Booth Content


Share This Content


Aesculap Biologics, LLC is currently conducting a Phase 3 clinical trial to bring NOVOCART® 3D to the United States from Europe where it originated and has been implanted in more than 9000 patients since 2003. NOVOCART 3D is an investigational biologic-device combination product consisting of an autologous chondrocyte implant derived from the patient’s own cartilage cells to regenerate articular cartilage in defects of the knee. The procedure involves an arthroscopic procedure to obtain a cartilage biopsy from a non-weight bearing location in the knee joint. The tissue is sent to the Aesculap Biologics manufacturing facility where the cartilage cells (chondrocytes) are isolated and grown in culture. Approximately three weeks later, the cells are added onto a collagen device and sent to the physician to be implanted into the defect. NOVOCART 3D is not approved for use in the United States or in Canada outside of the study.  For more information, visit


bronze sponsor, NOVOCART 3D®, Aesculap